Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069520 | 0.91 | TP53 (0.70) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL29266757 | 0.86 | NPC1 (0.75) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL3772286 | 0.86 | TP53 (0.83) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4167183 | 0.84 | TP53 (0.64) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4161699 | 0.82 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4159010 | 0.82 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4170594 | 0.82 | NPC1 (0.65) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4158350 | 0.82 | TP53 (0.66) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL4168776 | 0.82 | TP53 (0.66) | TP53NPC1JAK2RAB9APAX8 | |
| SCHEMBL16627492 | 0.81 | TP53 (0.70) | TP53NPC1JAK2RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| CN-101052397-B | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD | 2011-07-06 | — | — | CN | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
| CN-101052397-A | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-10 | — | — | CN | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| CN-1297554-C | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20040157874-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | disclosed |
| CN-1487939-A | Amido ether substituted imidazoquinolines | 3M | 2004-04-07 | — | — | CN | disclosed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-6660747-B2 | Contain ether and amide functionality at the 1-position; useful as immune response modifiers and can induce biosynthesis of various cytokines; useful in treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| EP-1341792-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TP53 279/4885NPC1 2650/4885JAK2 70/4885 |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | TP53 3872/4885NPC1 4454/4885JAK2 740/4885 |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TP53 279/4885NPC1 2650/4885JAK2 70/4885 |
| US-20040157874-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TP53 279/4885NPC1 2650/4885JAK2 70/4885 |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TP53 279/4885NPC1 2650/4885JAK2 70/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TP53 279/4885NPC1 2650/4885JAK2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.